In an exclusive interview with the European Medical Journal, Graham Clark, CEO of Phastar, discusses the current state of clinical research, the future role of AI in the industry, and how to build a values-driven company.
” The biggest challenge we face is balancing the need for speed and innovation with the imperative for quality, compliance and patient safety. With growing pressure to accelerate drug development timelines, particularly in high-demand therapeutic areas, sponsors and CROs face increasing complexity in trial design, data management and regulatory oversight. Fragmented systems, manual processes and patient recruitment hurdles can all delay progress and drive-up costs.
However, within this challenge lies a great opportunity: the transformation of clinical trials. Advances in AI, real-world data, decentralized trial models and adaptive designs are allowing us to run more efficient, responsive and inclusive trials than ever before. ”